Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 04:59 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR)
NCT03992131 · pharmaand GmbH · PHASE1/PHASE2 · terminated · last registry update 2024-01-16 · Breast cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Due to a change in development priorities, no further clinical development of the lucitanib plus rucaparib or lucitanib plus sacituzumab govitecan combinations is planned at this time.” | – | Registry record, pharmaand GmbH |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PARP1 in breast cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-02-14Results posted on the registry: Merck Sharp & Dohme LLC, Pembrolizumab + Olaparib (NCT04191135)
- 2023-11-18Phase 3 first posted: Tokyo Medical and Dental University, Systemic therapy for 12 weeks after primary registration + Same systemic therapy after secondary registration (NCT06135714)
- 2023-11-01Phase 3 first posted: AstraZeneca, Dato-DXd + Durvalumab (NCT06112379)
- 2023-10-13Results posted on the registry: AstraZeneca, Olaparib + MEDI4736 (NCT02734004)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision